Related references
Note: Only part of the references are listed.The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials
Richard G. B. Langley et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2015)
Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials
Richard G. Langley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Saving Medicare through Patient-Centered Changes - The Case of Injectables
Jeffrey S. Farroni et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomised, double-blind, placebo-controlled, phase II regimen-finding study
P. Rich et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
The potential of interleukin-17 to mediate hematopoietic response
Aleksandra Krstic et al.
IMMUNOLOGIC RESEARCH (2012)
Brodalumab, an Anti-Interleukin-17-Receptor Antibody for Psoriasis
Kim A. Papp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Anti-Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
Craig Leonardi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Randomized crossover study in patients with neuroendocrine tumors to assess patient preference for lanreotide Autogel® given by either self/partner or a health care professional
Viktor Johanson et al.
Patient Preference and Adherence (2012)
Adherence in the Treatment of Psoriasis: A Systematic Review
M. Augustin et al.
DERMATOLOGY (2011)
Assessment of self-injection experience in patients with rheumatoid arthritis: psychometric validation of the Self-Injection Assessment Questionnaire (SIAQ)
Dorothy Keininger et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2011)
IL-17 signaling in host defense against Candida albicans
Sarah L. Gaffen et al.
IMMUNOLOGIC RESEARCH (2011)
Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis
Andrew M. Lin et al.
JOURNAL OF IMMUNOLOGY (2011)
Integrative Responses to IL-17 and TNF-α in Human Keratinocytes Account for Key Inflammatory Pathogenic Circuits in Psoriasis
Andrea Chiricozzi et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2011)
Increased Th17 cells are accompanied by FoxP3(+) Treg cell accumulation and correlated with psoriasis disease severity
Li Zhang et al.
CLINICAL IMMUNOLOGY (2010)
Circulating Th17, Th22, and Th1 Cells Are Increased in Psoriasis
Shinji Kagami et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2010)
Overrepresentation of IL-17A and IL-22 Producing CD8 T Cells in Lesional Skin Suggests Their Involvement in the Pathogenesis of Psoriasis
Pieter C. M. Res et al.
PLOS ONE (2010)
Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis
Wolfgang Hueber et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Th17 Cytokines Stimulate CCL20 Expression in Keratinocytes In Vitro and In Vivo: Implications for Psoriasis Pathogenesis
Erin G. Harper et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)
Mechanisms of Disease: Interleukin-17 and Type 17 Helper T Cells.
Pierre Miossec et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Induction of IL-17+ T cell trafficking and development by IFN-γ:: Mechanism and pathological relevance in psoriasis
Ilona Kryczek et al.
JOURNAL OF IMMUNOLOGY (2008)
Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes
Jerome Pene et al.
JOURNAL OF IMMUNOLOGY (2008)
Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells
Michelle A. Lowes et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2008)
Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses
Lisa C. Zaba et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
Share Paper
